Medasense Biometrics Ltd.
Medasense Biometrics Ltd. is dedicated to transforming pain management through its innovative NOL® technology, which quantifies pain responses to personalize treatment and optimize care. The company aims to address the global challenge of pain, which affects millions and incurs significant healthcare costs, by providing objective measures for pain assessment and management.
Medasense Biometrics Ltd.
2436 Emrick Boulevard, Bethlehem, PA 18020, USA
What We Do
The PMD-200™ is a monitoring device that quantifies the physiological response to pain (nociception) in critical care settings, enabling clinicians to assess pain and personalize analgesic treatment.
NOLedge™ is an agile physiological insights platform that quantifies the physiological impact of pain to improve control, compliance, and outcomes in clinics and home care settings.
Diagnostics
Key People
VP Clinical & Market Development
VP OF SALES
VP R&D
Member of Scientific Advisory Board
News & Updates
NOL has been featured in Nature’s latest article on the search for objective measures of pain.
A study found that monitoring pain levels during surgery with NOL can help reduce intraoperative opioid usage and postoperative pain up to 3 days after surgery.
Medasense announces a strategic partnership with Nihon Kohden for the exclusive distribution of its pain monitoring device in Japan.
Join us for the NOL-Nociception Monitoring Breakfast meeting in San Francisco on October 15, 2023.
Attend the NOL Dinner Reception on October 20, 2024, in Philadelphia.
An article discussing the importance of nociception monitoring in anesthesia.